LC conceived of the work. LC and QT carried out the gene cloning and RNA expression analysis of LCMR1 in normal human tissues. ZL prepared GST-LCMR1 protein and antibody. CL participated in the qPCR and drafted the manuscript. ZL and XM performed immunohistochemistry analysis. CL and YL carried out qPCR. YZ, ZY, and PW collected the cases and sections. LC participated in the design and coordination

and supervised the whole study. All authors read and approved the final manuscript. All authors read and approved the final manuscript.”
“Background Follicular lymphoma is the most common type of indolent non-hodgkin lymphoma (NHL) in Western countries and is typically characterized by recurrence of disease. There is usually a pattern of repeated remissions and relapses until patients become refractory to treatment. The duration of remissions becomes shorter with repeated induction attempts. Transformation to more aggressive NHL occurs in selleck RAD001 research buy 15% to 50% of the patients at 5 years.After first relapse patients in otherwise good health are candidate for

salvage chemotherapy: combination chemotherapy, immunotherapy, and for some patients with good performance status and responsive disease, myeloablative therapy with stem-cell rescue. A number of cytotoxic agents in combination are active in this patient population and FCR regimen has provided encouraging results as initial or salvage therapy in patients with CLL or indolent NHL [1, 2]. Radioimmunotherapy is also an excellent modality in the treatment of NHL; the target antigen, radionuclide emission properties, and chemical stability of radioimmunoconjugates

are important factors that contribute to the effectiveness of RIT.90 Yttrium can deliver a high beta energy to tumor (2-3 MeV) and 90 Yttrium Ibritumomab Tiuxetan ( 90 Y -RIT ) – Zevalin® – consists of the anti-CD20 monoclonal antibody Adenosine ibritumomab (an IgG1k antibody which is the murine parent immunoglobulin to rituximab) covalently bound to the chelating agent tiuxetan and radiolabeled with 90 Yttrium. Furthermore recently FIT study has shown that consolidation of first remission with 90 Yttrium in advance-stage follicular lymphoma is highly effective with no unexpected toxicities, prolonging progression free survival (PFS) by 2 years [3, 4]. Then consolidation with 90 Yttrium after first line induction therapy, may allow more patients, with disseminated disease at diagnosis, to benefit from radioimmunotherapy and may present an attractive treatment option, particulary in older patients (age ≥ 60 years) who represent rougly 50% of patients with newly diagnosed indolent NHL. 90 Y-RIT also has been reported to be effective in patients with relapsed or refractory FL [5–7]. In this article we describe our experience with 90 Y -RIT consolidation in nine patients relapsed with grade 1 and 2 FL patients, responding to FCR.